Jennifer Howitt Anolik

Jennifer Howitt Anolik

Auto-generated profile, based on publicly available information

Jennifer Howitt Anolik

Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
Eddie A. JamesEddie A. James
Eddie A. James
FZFan Zhang
Fan Zhang
KWKevin Wei
Kevin Wei
KSKamil Slowikowski
Kamil Slowikowski
CFChamith Y. Fonseka
Chamith Y. Fonseka
SRSoumya Raychaudhuri
Soumya Raychaudhuri

1 October 2018 in Immunity
Verified
Journal Article
Closed access
SJScott A. Jenks
Scott A. Jenks
KCKevin S. Cashman
Kevin S. Cashman
EZEsther Zumaquero
Esther Zumaquero
UMUrko M. Marigorta
Urko M. Marigorta
APAakash V. Patel
Aakash V. Patel
ISIgnacio Sanz
Ignacio Sanz

17 June 2019 in Nature Immunology
Verified
Journal Article
Open access
PDF file
TNthe Accelerating Medicines Partnership in SLE network
the Accelerating Medicines Partnership in SLE network
AAArnon Arazi
Arnon Arazi
DRDeepak A. Rao
Deepak A. Rao
CBCeline C. Berthier
Celine C. Berthier
ADAnne Davidson
Anne Davidson
BDBetty Diamond
Betty Diamond
Lupus nephritis is a potentially fatal autoimmune disease for which the current treatment is ineffective and often toxic. To develop mechanistic hypotheses of disease, we analyzed kidney samples from patients with lupus nephritis and from healthy control subjects using single-cell RNA sequencing. Our analysis revealed 21 subsets of leukocytes active in disease, including multiple populations of myeloid cells, T cells, natural killer cells and B cells that demonstrated both pro-inflammatory responses and inflammation-resolving responses. We found evidence of local activation of B cells correlated with an age-associated B-cell signature and evidence of progressive stages of monocyte differentiation within the kidney. A clear interferon response was observed in most cells. Two chemokine receptors, CXCR4 and CX3CR1, were broadly expressed, implying a potentially central role in cell trafficking. Gene expression of immune cells in urine and kidney was highly correlated, which would suggest that urine might serve as a surrogate for kidney biopsies.

5 August 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
RLR. John Looney
R. John Looney
JAJennifer H. Anolik
Jennifer H. Anolik
DCDebbie Campbell
Debbie Campbell
RFRaymond E. Felgar
Raymond E. Felgar
FYFaith Young
Faith Young
ISIñaki Sanz
Iñaki Sanz
Objective: Safer and more effective therapies are needed for the treatment of systemic lupus erythematosus (SLE). B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE.Methods: A phase I/II dose‐escalation trial of rituximab added to ongoing therapy in SLE was conducted. Rituximab was administered as a single infusion of 100 mg/m2 (low dose), a single infusion of 375 mg/m2 (intermediate dose), or as 4 infusions (1 week apart) of 375 mg/m2 (high dose). CD19+ lymphocytes were measured to determine the effectiveness of B cell depletion. The Systemic Lupus Activity Measure (SLAM) score was used as the primary outcome for clinical efficacy.Results: Rituximab was well tolerated in this patient population, with most experiencing no significant adverse effects. Only 3 serious adverse events, which were thought to be unrelated to rituximab administration, were noted. A majority of patients (11 of 17) had profound B cell depletion (to <5 CD19+ B cells/μl). In these patients, the SLAM score was significantly improved at 2 and 3 months compared with baseline (P = 0.0016 and P = 0.0022, respectively, by paired t‐test). This improvement persisted for 12 months, despite the absence of a significant change in anti–double‐stranded DNA antibody and complement levels. Six patients developed human antichimeric antibodies (HACAs) at a level ≥100 ng/ml. These HACA titers were associated with African American ancestry, higher baseline SLAM scores, reduced B cell depletion, and lower levels of rituximab at 2 months after initial infusion.Conclusion: Rituximab therapy appears to be safe for the treatment of SLE and holds significant therapeutic promise, at least for the majority of patients experiencing profound B cell depletion. Based on these results, controlled trials of rituximab appear to be warranted.

15 May 2007 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
CWChungwen Wei
Chungwen Wei
JAJennifer Anolik
Jennifer Anolik
ACAmedeo Cappione
Amedeo Cappione
BZBo Zheng
Bo Zheng
APAimee Pugh-Bernard
Aimee Pugh-Bernard
ISIñaKi Sanz
IñaKi Sanz
Laboratory experiments have shown that parents who believe their child’s abilities are fixed engage with their child in unconstructive, performance-oriented ways. We show that children of parents with such “fixed mindsets” have lower reading skills, even after controlling for the child’s previous abilities and the parents’ socioeconomic status. In a large-scale randomized field trial (Nclassrooms = 72; Nchildren = 1,587) conducted by public authorities, parents receiving a reading intervention were told about the malleability of their child’s reading abilities and how to support their child by praising his/her effort rather than his/her performance. This low-cost intervention increased the reading and writing achievements of all participating children—not least immigrant children with non-Western backgrounds and children with low-educated mothers. As expected, effects were even bigger for parents who before the intervention had a fixed mindset. Significance Many large-scale parent interventions turn out to be ineffective, particularly for socioeconomically disadvantaged families—possibly because some parents believe that their children’s reading skills are relatively fixed and unresponsive to practicing. This study shows large and consistent effects on both reading and writing skills of second-grade children whose parents received a few children’s books and information about the value of supporting children when learning to read. Effects are at least as large for children with immigrant background or low-educated mothers as for other children—and biggest for those children whose parents before the intervention believed reading abilities to be relatively fixed. The study thereby shows a direction for effective parent interventions.

4 November 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JAJennifer H. Anolik
Jennifer H. Anolik
JBJennifer Barnard
Jennifer Barnard
ACAmedeo Cappione
Amedeo Cappione
APAimee E. Pugh‐Bernard
Aimee E. Pugh‐Bernard
RFRaymond E. Felgar
Raymond E. Felgar
ISIñaki Sanz
Iñaki Sanz
Objective: B lymphocyte depletion has recently emerged as a promising approach to the treatment of systemic lupus erythematosus (SLE). As part of a phase I/II dose‐ranging trial of rituximab in the treatment of SLE, we evaluated the fate of discrete B cell subsets in the setting of selective depletion by anti‐CD20 monoclonal antibody and during the B cell recovery phase.Methods: B cell depletion and phenotype were examined by flow cytometry of peripheral blood mononuclear cells for CD19, CD20, CD27, IgD, and CD38 expression. Changes in autoreactive B lymphocytes and plasma cells were assessed by determination of serum autoantibody levels (anti–double‐stranded DNA and VH4.34) and by direct monitoring of a unique autoreactive B cell population bearing surface antibodies whose heavy chain is encoded by the VH4.34 gene segment.Results: Compared with normal controls, SLE patients displayed several abnormalities in peripheral B cell homeostasis at baseline, including naive lymphopenia, expansion of a CD27−,IgD− (double negative) population, and expansion of circulating plasmablasts. Remarkably, these abnormalities resolved after effective B cell depletion with rituximab and immune reconstitution. The frequency of autoreactive VH4.34 memory B cells also decreased 1 year posttreatment, despite the presence of low levels of residual memory B cells at the point of maximal B cell depletion and persistently elevated serum autoantibody titers in most patients.Conclusion: This study is the first to show evidence that in SLE, specific B cell depletion therapy with rituximab dramatically improves abnormalities in B cell homeostasis and tolerance that are characteristic of this disease. The persistence of elevated autoantibody titers may reflect the presence of low levels of residual autoreactive memory B cells and/or long‐lived autoreactive plasma cells.